446 related articles for article (PubMed ID: 14576474)
21. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways.
Cao D; Maitra A; Saavedra JA; Klimstra DS; Adsay NV; Hruban RH
Mod Pathol; 2005 Jun; 18(6):752-61. PubMed ID: 15696124
[TBL] [Abstract][Full Text] [Related]
22. Use of mesothelin as a marker for mesothelial cells in cytologic specimens.
Kachali C; Eltoum I; Horton D; Chhieng DC
Semin Diagn Pathol; 2006 Feb; 23(1):20-4. PubMed ID: 17044192
[TBL] [Abstract][Full Text] [Related]
23. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary.
Cao D; Ji H; Ronnett BM
Int J Gynecol Pathol; 2005 Jan; 24(1):67-72. PubMed ID: 15626919
[TBL] [Abstract][Full Text] [Related]
24. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma.
Miettinen M; Limon J; Niezabitowski A; Lasota J
Am J Surg Pathol; 2001 May; 25(5):610-7. PubMed ID: 11342772
[TBL] [Abstract][Full Text] [Related]
25. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
[TBL] [Abstract][Full Text] [Related]
26. Expression of a new mucin-type glycoprotein in select epithelial dysplasias and neoplasms detected immunocytochemically with Mab A-80.
Shin SS; Gould VE; Gould JE; Warren WH; Gould KA; Yaremko ML; Manderino GL; Rittenhouse HG; Tomita JT; Jansson DS
APMIS; 1989 Dec; 97(12):1053-67. PubMed ID: 2611021
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the specificity by immunohistology of a monoclonal antibody to a novel epithelial antigen of ovarian carcinomas.
Mariani-Costantini R; Agresti R; Colnaghi MI; Ménard S; Andreola S; Rilke F
Pathol Res Pract; 1985 Aug; 180(2):169-80. PubMed ID: 3903701
[TBL] [Abstract][Full Text] [Related]
28. Applications of monoclonal antibodies in clinical cytology as exemplified by studies with monoclonal antibody B72.3. The George N. Papanicolaou award lecture.
Johnston WW
Acta Cytol; 1987; 31(5):537-56. PubMed ID: 3314301
[TBL] [Abstract][Full Text] [Related]
29. Localization of mesothelin in epithelial ovarian cancer.
Hassan R; Kreitman RJ; Pastan I; Willingham MC
Appl Immunohistochem Mol Morphol; 2005 Sep; 13(3):243-7. PubMed ID: 16082249
[TBL] [Abstract][Full Text] [Related]
30. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT
Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468
[TBL] [Abstract][Full Text] [Related]
31. Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia.
Drapkin R; Crum CP; Hecht JL
Hum Pathol; 2004 Aug; 35(8):1014-21. PubMed ID: 15297969
[TBL] [Abstract][Full Text] [Related]
32. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
Ordóñez NG
Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
[TBL] [Abstract][Full Text] [Related]
33. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
Young RH
Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
[TBL] [Abstract][Full Text] [Related]
34. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
Miettinen M; Sarlomo-Rikala M
Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
[TBL] [Abstract][Full Text] [Related]
35. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.
Miettinen M; McCue PA; Sarlomo-Rikala M; Rys J; Czapiewski P; Wazny K; Langfort R; Waloszczyk P; Biernat W; Lasota J; Wang Z
Am J Surg Pathol; 2014 Jan; 38(1):13-22. PubMed ID: 24145643
[TBL] [Abstract][Full Text] [Related]
36. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
37. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
Ordóñez NG
Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic value of IMP3 and mesothelin in differentiating pancreatic ductal adenocarcinoma from chronic pancreatitis.
Ibrahim DA; Abouhashem NS
Pathol Res Pract; 2016 Apr; 212(4):288-93. PubMed ID: 26874572
[TBL] [Abstract][Full Text] [Related]
39. Applications of immunocytochemistry to clinical cytology.
Johnston WW; Szpak CA; Thor A; Simpson JF; Schlom J
Cancer Invest; 1987; 5(6):593-611. PubMed ID: 3327572
[TBL] [Abstract][Full Text] [Related]
40. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
Ordóñez NG
Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
